AbbVie Completes Transformative Acquisition of Allergan

Creates biopharmaceutical company with leadership positions in key therapeutic areas

Follow Asdaf News on

Newsgate360 – NORTH CHICAGO, Ill.,: AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced on Friday that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

“We are pleased to reach this important milestone for the Company, its employees, shareholders and the patients we serve” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.

“Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our Company. The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us. I am proud of both organizations and look forward to the opportunities ahead.”

Well-Positioned for Long-Term Growth in Key Therapeutic Areas
The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in Immunology, with Humira®, and recently launched Skyrizi TM and RinvoqTM, and Hematologic Oncology, with Imbruvica® and Venclexta®. Allergan provides new growth opportunities in Neuroscience, with Botox® Therapeutics, Vraylar® and UbrelvyTM and a global aesthetics business, with leading brands including Botox® and Juvederm®.

This diversified on-market portfolio will drive the existing AbbVie growth platform to approximately $30 billion in revenues in full year 2020, with combined revenues of approximately $50 billion. It also positions the Company for enhanced long-term growth potential, a growing dividend and investment in innovation in each of its therapeutic categories. The Company anticipates rapidly paying down the incremental debt with its increased operating cash flows.

Additionally, in connection with the closing of the transaction, the AbbVie Board of Directors has elected Thomas C. Freyman, retired Executive Vice President and Chief Financial Officer, Abbott to join the AbbVie board. Mr. Freyman recently served on the Allergan Board of Directors.

Show More

Related Articles


  1. Amazing! This website looks just like my old
    one! It’s with a entirely different topic but it has just about exactly
    the same layout and design. Excellent choice of colors!

    Also visit my blog … BertVDruck

  2. Appreciating the time and energy you put into
    your website and detailed information you provide. It’s good to
    come across a blog every once in a while that isn’t the
    same outdated rehashed material. Excellent read! I’ve bookmarked your site and I’m including your RSS feeds to my Google account.

  3. Undeniably consider that which you said. Your favourite justification seemed to be in the web the easiest factor
    to have in your mind of. I only say for your needs, I definitely get annoyed whilst other folks think of concerns which they
    plainly will not recognise about. You managed to hit the nail upon the best and outlined out the
    whole thing without having need unwanted effect , people can have a signal.

    Will probably be again to obtain additional.

    Thank you

  4. You’re so cool! I do not believe I’ve read through anything like this before.
    So great to discover another person with some genuine thoughts on this topic.
    Seriously.. thanks for starting this up. This web site is something that’s needed on the internet, someone with some

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button